134 related articles for article (PubMed ID: 2469601)
1. Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A.
von der Helm K; Gürtler L; Eberle J; Deinhardt F
FEBS Lett; 1989 Apr; 247(2):349-52. PubMed ID: 2469601
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.
Seelmeier S; Schmidt H; Turk V; von der Helm K
Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6612-6. PubMed ID: 3045820
[TBL] [Abstract][Full Text] [Related]
3. The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodeficiency virus 1.
Grinde B; Hungnes O; Tjøtta E
AIDS Res Hum Retroviruses; 1989 Jun; 5(3):269-74. PubMed ID: 2471542
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of aspartic proteinase inhibitors related to pepstatin.
Gunn JM; Owens RA; Liu WS; Glover GI
Acta Biol Med Ger; 1981; 40(10-11):1547-53. PubMed ID: 6805191
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
6. Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.
Rich DH
J Med Chem; 1985 Mar; 28(3):263-73. PubMed ID: 3882966
[No Abstract] [Full Text] [Related]
7. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases.
Richards AD; Roberts R; Dunn BM; Graves MC; Kay J
FEBS Lett; 1989 Apr; 247(1):113-7. PubMed ID: 2651157
[TBL] [Abstract][Full Text] [Related]
8. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.
Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl sulfoxide inhibits human immunodeficiency virus production in vitro.
Viza D; Aranda-Anzaldo A; Zompetti C; Vich JM
Intervirology; 1991; 32(1):59-64. PubMed ID: 1707866
[TBL] [Abstract][Full Text] [Related]
11. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
[No Abstract] [Full Text] [Related]
12. Purification and properties of a pepstatin-insensitive carboxyl proteinase from a gram-negative bacterium.
Oda K; Sugitani M; Fukuhara K; Murao S
Biochim Biophys Acta; 1987 Mar; 923(3):463-9. PubMed ID: 3548827
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of infected cell appearance as a determinant of number of human immunodeficiency virus-1 infectious units.
Cory JM; Ohlsson-Wilhelm BM; Steck ME; Smithgall MD; Rozday V; Eyster ME; Rapp F
AIDS Res Hum Retroviruses; 1989 Feb; 5(1):97-106. PubMed ID: 2497763
[TBL] [Abstract][Full Text] [Related]
14. Pepstatin inhibition of rat myocardial acid protease.
Hokins BE; Smith TW
Recent Adv Stud Cardiac Struct Metab; 1976 May 26-29; 12():439-43. PubMed ID: 1031998
[TBL] [Abstract][Full Text] [Related]
15. Comparison of core antigen (p24) assay and reverse transcriptase activity for detection of human immunodeficiency virus type 1 replication.
Land S; Beaton F; McPhee DA; Gust ID
J Clin Microbiol; 1989 Mar; 27(3):486-9. PubMed ID: 2469698
[TBL] [Abstract][Full Text] [Related]
16. Leukocyte protease activities in myotonic dystrophy: studies on effects of protease inhibitors.
Goto I; Shinno N; Kuroiwa Y
Eur Neurol; 1987; 26(2):126-8. PubMed ID: 3549315
[TBL] [Abstract][Full Text] [Related]
17. Chymostatin can combine with pepstatin to eliminate extracellular protease activity in cultures of Aspergillus niger NRRL-3.
Ahamed A; Singh A; Ward OP
J Ind Microbiol Biotechnol; 2007 Feb; 34(2):165-9. PubMed ID: 17177024
[TBL] [Abstract][Full Text] [Related]
18. Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation.
Yoshida H; Okamoto K; Iwamoto T; Sakai E; Kanaoka K; Hu JP; Shibata M; Hotokezaka H; Nishishita K; Mizuno A; Kato Y
J Biochem; 2006 Mar; 139(3):583-90. PubMed ID: 16567424
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cysteine proteinase activity by Z-Phe-Phe-diazomethane and of aspartic proteinase activity by pepstatin in different organs from some animals and isolated cells from rat liver.
Riemann S; Kirschke H; Wiederanders B; Brouwer A; Shaw E; Bohley P
Acta Biol Med Ger; 1982; 41(1):83-8. PubMed ID: 7051705
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the human immunodeficiency virus type 1 and 2 proteases by hybrid gene construction and trans-complementation.
Le Grice SF; Ette R; Mills J; Mous J
J Biol Chem; 1989 Sep; 264(25):14902-8. PubMed ID: 2670928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
